» Articles » PMID: 36975693

Preclinical Potential of Probiotic-Loaded Novel Gelatin-Oil Vaginal Suppositories: Efficacy, Stability, and Safety Studies

Overview
Journal Gels
Date 2023 Mar 28
PMID 36975693
Authors
Affiliations
Soon will be listed here.
Abstract

The current study describes a suppository base composed of aqueous gelatin solution emulsifying oil globules with probiotic cells dispersed within. The favorable mechanical properties of gelatin to provide a solid gelled structure, and the tendency of its proteins to unravel into long strings that interlace when cooled, lead to a three-dimensional structure that can trap a lot of liquid, which was exploited herein to result in a promising suppository form. The latter maintained incorporated probiotic spores of Unique IS-2 in a viable but non-germinating form, preventing spoilage during storage and imparting protection against the growth of any other contaminating organism (self-preserved formulation). The gelatin-oil-probiotic suppository showed uniformity in weight and probiotic content (23 ± 2.481 × 10 cfu) with favorable swelling (double) followed by erosion and complete dissolution within 6 h of administration, leading to the release of probiotic (within 45 min) from the matrix into simulated vaginal fluid. Microscopic images indicated presence of probiotics and oil globules enmeshed in the gelatin network. High viability (24.3 ± 0.46 × 10), germination upon application and a self-preserving nature were attributed to the optimum water activity (0.593 a) of the developed composition. The retention of suppositories, germination of probiotics and their in vivo efficacy and safety in vulvovaginal candidiasis murine model are also reported.

Citing Articles

The Female Reproductive Tract Microbiota: Friends and Foe.

Kumar L, Dwivedi M, Jain N, Shete P, Solanki S, Gupta R Life (Basel). 2023; 13(6).

PMID: 37374096 PMC: 10301250. DOI: 10.3390/life13061313.

References
1.
Xie H, Feng D, Wei D, Mei L, Chen H, Wang X . Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev. 2017; 11:CD010496. PMC: 6486023. DOI: 10.1002/14651858.CD010496.pub2. View

2.
Husain S, Allotey J, Drymoussi Z, Wilks M, Fernandez-Felix B, Whiley A . Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. BJOG. 2019; 127(2):275-284. PMC: 6973149. DOI: 10.1111/1471-0528.15675. View

3.
Mei Z, Li D . The role of probiotics in vaginal health. Front Cell Infect Microbiol. 2022; 12:963868. PMC: 9366906. DOI: 10.3389/fcimb.2022.963868. View

4.
Kumherova M, Vesela K, Kosova M, Masata J, Horackova S, Smidrkal J . Novel Potential Probiotic Lactobacilli for Prevention and Treatment of Vulvovaginal Infections. Probiotics Antimicrob Proteins. 2020; 13(1):163-172. DOI: 10.1007/s12602-020-09675-2. View

5.
Foxman B, Muraglia R, Dietz J, Sobel J, Wagner J . Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013; 17(3):340-5. DOI: 10.1097/LGT.0b013e318273e8cf. View